



**Our Ref: IVD000592**

Dr Ari Raju  
**Lab21 Healthcare Ltd**  
Unit 29, Dreadnought Trading Estate  
Bridport , DT6 5BU  
United Kingdom

**MHRA**

ERA2 4<sup>th</sup> floor Yellow,  
151 Buckingham Palace Road  
Victoria  
London SW1W 9SZ  
United Kingdom

**22<sup>nd</sup> Feb 2016**

Dear Dr Raju,

**MEDICAL DEVICES REGULATIONS 2002: REGULATION 44**  
**Registration of Persons Placing In vitro Diagnostic Medical Devices on the Market**

Thank you for informing the Competent Authority of your company's details and for supplying the medical device information in regards to the change to the original notification dated (21/10/11).

**The change(s) to registration has been recorded based on your declaration that you have determined that the device(s) fall within the definition of "in vitro diagnostic medical device", and that you have classified it/them correctly taking into account the intended purpose(s) and mode(s) of action. In accepting your registration, I should make clear that the Competent Authority does not examine each individual notification and therefore cannot and does not necessarily endorse these determinations. Neither does this letter represent any form of accreditation or approval by the UK Competent Authority.**

Your registration is based upon your declaration on the RG3 form and means that you should now be operating under the In Vitro Diagnostic Medical Devices Directive and the 2002 Regulations for the products you asked us to register, by fully complying with the essential requirements, CE marking those products or labelling them as such.

**If you stop placing devices on the market or if you are not complying with the Regulations you should inform us as required by the Regulations. You should be aware that it is an offence to place on the market CE marked devices that do not comply with the Regulations.**

The information you provided has been recorded against the reference number shown at the top of this letter, which we ask you to quote in all future correspondence and communications.

Please inform us of any changes to:

- the company information
- additional generic groups of devices or, for Annex II or Self-Test devices, additional devices
- discontinuation of a generic group of devices or, for Annex II or Self-Test devices, discontinuation of devices

Please use RG3, the Registration form, to tell us about any of these changes. A fee of £70 is payable for each change or set of changes notified.

Thank you for registering the following generic groups of devices

***Part 5: IVDs which are not Annex II and not self-test devices***

***For reagents, reagent products, calibration and control materials:  
group by common technological characteristics and/or analytes***

***New products:  
None***

***For performance evaluation:***  
***None***

***Neither:***

- 1 Adenovirus***
- 2 Other Syphilis Reagents***
- 3 Streptococci***
- 4 Staphylococci***
- 5 ds DNA - Antibodies***
- 6 Mononucleosis - Rapid Test***
- 7 C-Reactive Protein***
- 8 Rheumatoid Factors***
- 9 Salmonella Antibody Assays***
- 10 Human Chorionic Gonadotropin Total***
- 11 Syphilis Antibody Assays Total***
- 12 Rotavirus***
- 13 Proteus***
- 14 Brucella***
- 15 Other EBV Reagents***
- 16 Syphilis Antibody Assays Total***
- 17 ds DNA – Antibodies***

***For other IVDs, group by appropriate indications***

***New products:***  
***None***

***For performance evaluation:***  
***None***

***Neither:***  
***None***

***Part 6: IVDs which are Annex II or self-test devices***

***For reagents, reagent products, calibration and control materials:***  
***group by common technological characteristics and/or analytes***

***New products:***  
***None***

***For performance evaluation:***  
***None***

***Neither:***

- 1. Anti A Monoclonal - Anti A (ABO sera)***
- 2. Anti B Monoclonal - Anti A (ABO sera)***
- 3. Anti AB Monoclonal - Anti AB (ABO sera)***
- 4. Anti D IgM Monoclonal - Anti D IgM (Anti – Rh D)***
- 5. Anti D (IgG/IgM) Monoclonal - Anti D (IgG/IgM) (Anti – Rh D)***
- 6. Anti-Human Globulin - Anti-Human Globulin***

***For other IVDs, group by appropriate indications***

***New products:***  
***None***

***For performance evaluation:***  
***None***

***Neither:***  
***None***

If you have any queries regarding your registration, please do not hesitate to contact us.

Yours sincerely



***Ms Angela Bartley***  
**European Regulatory Affairs**  
**(ERA2) Office Manager**

**Direct Line: 0203 080 7149**  
**Email:**  
**[angela.bartley@mhra.gsi.gov.uk](mailto:angela.bartley@mhra.gsi.gov.uk)**  
**Web: [www.mhra.gov.uk](http://www.mhra.gov.uk)**